DALLAS - June 24, 2021 - Mutations in a gene related to HER2, a gene frequently implicated in breast cancers and a variety of other malignancies, can amplify activity that spurs tumor growth, a new ...
BioNTech is flattering Daiichi Sankyo through imitation. Six months after picking up an Enhertu rival, the German biotech has paid $70 million upfront to MediLink Therapeutics for an antibody-drug ...
Patritumab deruxtecan, with or without letrozole, showed similar efficacy to chemotherapy in high-risk HR-positive, HER2-negative breast cancer, with lower severe side effects. The SOLTI VALENTINE ...
“[...] we discovered that the surrounding liver EC microenvironment plays a key role in activating HER3 and promoting cell survival in mCRC and mPDAC ...
HER3-DXd proved to be safe and efficacious in treating patients with HER3-expressing metastatic breast cancer, recent study results showed. The HER3 protein is overexpressed in approximately 30% to 50 ...
Phase I study of volasertib (BI 6727) combined with afatinib (BIBW 2992) in advanced solid tumors. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include ...
Elevation Oncology (ELEV) announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to ...
Please provide your email address to receive an email when new articles are posted on . In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is ...
Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results